James Mulay sold $585k of CGON
director at CG Oncology, Inc.. 11,145 shares at an average of $52.47, traded Jan 9, 2026, filed Jan 13, 2026.
Score components
- +15RoleDirector
- +19Trade size$585k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-011756, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 9, 2026 | MOption exercise Common Stock10b5-1 | +654 | $3.72 | $2,433 | 654 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -654 | $44.16 | $29k | 0 | Jan 13, 2026 |
| Jan 9, 2026 | MOption exercise Common Stock10b5-1 | +10,491 | $12.59 | $132k | 10,491 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -10,491 | $52.99 | $556k | 0 | Jan 13, 2026 |
| Jan 9, 2026 | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -654 | $0.00 | $0 | 1,308 | Jan 13, 2026 |
| Jan 9, 2026 | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -10,491 | $0.00 | $0 | 5,240 | Jan 13, 2026 |
Related signals
Other insiders at CG Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | CG Oncology, Inc. | Leonard E Post director | $73k 1,000 shares | -100% | |
| 10Weak | CG Oncology, Inc. | James Mulay director | $125k 1,964 shares | -300% | |
| 6Weak | CG Oncology, Inc. | Leonard E Post director | $41k 1,000 shares | -100% | |
| 14Weak | CG Oncology, Inc. | Leonard E Post director | $43k 1,000 shares | -100% | |
| 21Weak | CG Oncology, Inc. | James Mulay director | $260k 5,903 shares | -100% | |
| 20Weak | CG Oncology, Inc. | Leonard E Post director | $200k 5,000 shares | -100% | |
| 26Weak | CG Oncology, Inc. | James Mulay director | $500k 12,755 shares | -100% | |
| 31Weak | CG Oncology, Inc. | James Mulay director | $885k 22,686 shares | -119% | |
| 21Weak | CG Oncology, Inc. | Leonard E Post director | $35k 1,000 shares | -100% | |
| 37Weak | CG Oncology, Inc. | Brian Guan-Chyun Liu director | $50M 1,515,151 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.